Home > Products > Product Information
Kailikang®Urinary Kallidinogenase for Injection
Urinary Kallidinogenase for Injection
When the global-pioneering new drug - Kailikang® (Kallidinogenase for Injection) was launched to the market, it heralded a new era for the treatment of cerebrovascular disease. China is the first country in the world to own such a drug.
Mild to medium acute thrombotic cerebral infarction.
In 1996, it was listed in national key projects for the R&D of innovative drugs.
In 2001, it was included inthe National Torch Programme.
In 2005, it was launched into Chinese market as globally innovative drug.
In 2010, it was recommended by the Chinese guideline for the treatment of ischemic cerebral infarction.
In 2011, it won the second prize of the National Science and Technology Progress Award
Product ReviewPrescribing Information

Urinary kallidinogenase is one kind of proteolytic enzyme extracted from human urine,which can convert kininogen to kinin and kallidin. In vitro study indicates that urinary kallidinogenase could dilate ex vivo artery, inhibit plateletaggregation, and promote deformability and oxygen dissociation ability of hemocyte. Animal experiments indicate that intravenous injection of urinary kallidinogenase can increase intervertebral artery flow, common carotid artery flow , femoral artery blood flow , posterior limb blood flow of anesthesiadogs and muscle blood flow of rabbits. When cerebral microvessel injury of rabbits is induced by injecting of glass bead into the internal carotid artery,intravenous injection of urinary kallidinogenase could dilate cerebral vessels,increase hemoglobin level in cerebral blood, inhibit the expansion of the cerebral infarct area, prevent the decrease of glucose and oxygen absorption of the brain caused by infarct, improve glucose metabolism and relieve spontaneous cortical electroencephalogram abnormity.


Urinary Kallidinogenasefor Injection


[Name]

Generic Name: Urinary Kallidinogenase for Injection

Brand Name: Kailikang®

English Name: Urinary Kallidinogenase for Injection

Chinese Pinyin: Zhusheyong Youruikelin


[Indication]

Mild to medium acute thrombotic cerebral infarction.


[Strength]

0.15 PNA  IU/vial.


[Pharmacology]

 Urinary kallidinogenase is a kind of proteolyticenzyme extracted from human urine, which can convert kininogen to kinin and kallidin. In vitro study indicates that urinary kallidinogenase could dilate exvivo artery, inhibit platelet aggregation, promote deformability and oxygendissociation ability of hemocyte. Animal experiments indicate that intravenousinjection of urinary kallidinogenase can increase intervertebral artery, commoncarotid artery and femoral artery blood flow as well as posterior limb bloodflow of anesthesia dogs and muscle blood flow of rabbits. When cerebralmicrovessel injury of rabbits is induced by injection of glass bead into aninternal carotid artery, intravenous injection of urinary kallidinogenase coulddilate cerebral vessels, increase hemoglobin level in cerebral blood, inhibitthe expansion of the cerebral infarct area, prevent the decrease of glucose and oxygen absorption of the brain caused by infarct, improve glucose metabolismand relieve spontaneous cortical electroencephalogram abnormity.